Delivery Order SPE2DB22D2006-SPE2DB25FW2AE
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Ondansetron HCL 4 mg tablets (30-count packaging) with a contract value of $3,436.96. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract has an ultimate completion date...
- The Defense Logistics Agency (DLA) awarded a $11,073.06 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ondansetron HCl 4 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 10, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $35,990.01. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of September 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,110.41 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500 count) on August 14, 2025, with ultimate completion scheduled for August 15, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform this work at its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Ondansetron HCL 4 mg tablets (30-count packages) under a firm fixed-price contract with a ceiling value of $50,930.27. This non-set-aside delivery order is set to be completed by July 15, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 500 units, with a contract ceiling value of $4,238.10. This is a firm fixed-price delivery order with an ultimate completion date of September 9, 2025. The award was competitively procured with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,347.84 to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of September 4, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $11,924.12 on August 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order operates under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 4, 2025, for the supply of Ondansetron ODT 4 mg tablets in a 30-count package. This contract, valued at $10,430.70, is a firm fixed-price delivery order with an ultimate completion date of June 5, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Ondansetron HCL 4 mg tablets in quantities of 30 units. This non-set-aside, competitively awarded delivery order carries a ceiling value of $5,612.77 and features firm fixed pricing, with an ultimate completion date of July 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW2AEDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,923.09 to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30. The contract is a firm fixed price delivery order with no set-aside designation, indicating competitive award, and carries an ultimate completion date of June 27, 2025. Performance will be executed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical prime vendor for federal medical procurement, supplying a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems. The parent IDC encompasses specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains for use by the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 6/26/25 |